172.62 USD
+7.24 (+4.38%)
172.62 USD
0 (0%)
BIIB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BIIB is cheap, but on the other hand it scores bad on growth. This makes BIIB very considerable for value investing!
1. Profitability
1.1 Basic Checks
- BIIB had positive earnings in the past year.
- In the past year BIIB had a positive cash flow from operations.
- BIIB had positive earnings in each of the past 5 years.
- Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 5.51%, BIIB belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 8.84%, BIIB belongs to the top of the industry, outperforming 92.38% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 9.70%, BIIB belongs to the best of the industry, outperforming 94.86% of the companies in the same industry.
- BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is significantly below the industry average of 18.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- Looking at the Profit Margin, with a value of 15.98%, BIIB belongs to the top of the industry, outperforming 92.57% of the companies in the same industry.
- BIIB's Profit Margin has declined in the last couple of years.
- The Operating Margin of BIIB (28.50%) is better than 96.76% of its industry peers.
- BIIB's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 75.24%, BIIB belongs to the top of the industry, outperforming 83.81% of the companies in the same industry.
- BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
- The number of shares outstanding for BIIB has been increased compared to 1 year ago.
- The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
- BIIB has a better debt/assets ratio than last year.
2.2 Solvency
- BIIB has an Altman-Z score of 3.21. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BIIB (3.21) is better than 69.33% of its industry peers.
- BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
- The Debt to FCF ratio of BIIB (2.78) is better than 92.95% of its industry peers.
- A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
- The Debt to Equity ratio of BIIB (0.35) is worse than 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.21 |
ROIC/WACC1.15
WACC8.44%
2.3 Liquidity
- A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
- With a Current ratio value of 2.72, BIIB is not doing good in the industry: 68.38% of the companies in the same industry are doing better.
- A Quick Ratio of 2.04 indicates that BIIB has no problem at all paying its short term obligations.
- BIIB has a worse Quick ratio (2.04) than 73.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
- Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
- The Revenue has been growing slightly by 4.77% in the past year.
- Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 10.31, the valuation of BIIB can be described as very reasonable.
- BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.10% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.32. BIIB is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 11.17, the valuation of BIIB can be described as very reasonable.
- 98.10% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
- BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.31 | ||
| Fwd PE | 11.17 |
4.2 Price Multiples
- BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.48% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 98.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.19 | ||
| EV/EBITDA | 7.29 |
4.3 Compensation for Growth
- The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
- No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
172.62
+7.24 (+4.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/amc
Inst Owners96.04%
Inst Owner Change-0.04%
Ins Owners0.15%
Ins Owner Change0.74%
Market Cap25.32B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target193.25 (11.95%)
Short Float %3.05%
Short Ratio2.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.49%
PT rev (3m)11.58%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)-54.28%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.47%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.31 | ||
| Fwd PE | 11.17 | ||
| P/S | 2.52 | ||
| P/FCF | 11.19 | ||
| P/OCF | 10.32 | ||
| P/B | 1.39 | ||
| P/tB | 10.62 | ||
| EV/EBITDA | 7.29 |
EPS(TTM)16.74
EY9.7%
EPS(NY)15.46
Fwd EY8.96%
FCF(TTM)15.42
FCFY8.93%
OCF(TTM)16.73
OCFY9.69%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.44%
ROIC/WACC1.15
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status of BIOGEN INC (BIIB) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
How financially healthy is BIOGEN INC?
The financial health rating of BIOGEN INC (BIIB) is 7 / 10.